Department of Mechanical Engineering, Northwestern University, Evanston, Illinois 60208, USA.
Nano Lett. 2013 Jun 12;13(6):2448-57. doi: 10.1021/nl400423c.
The ability to precisely deliver molecules into single cells is of great interest to biotechnology researchers for advancing applications in therapeutics, diagnostics, and drug delivery toward the promise of personalized medicine. The use of bulk electroporation techniques for cell transfection has increased significantly in the past decade, but the technique is nonspecific and requires high voltage, resulting in variable efficiency and low cell viability. We have developed a new tool for electroporation using nanofountain probe (NFP) technology, which can deliver molecules into cells in a manner that is highly efficient and gentler to cells than bulk electroporation or microinjection. Here we demonstrate NFP electroporation (NFP-E) of single HeLa cells within a population by transfecting them with fluorescently labeled dextran and imaging the cells to evaluate the transfection efficiency and cell viability. Our theoretical analysis of the mechanism of NFP-E reveals that application of the voltage creates a localized electric field between the NFP cantilever tip and the region of the cell membrane in contact with the tip. Therefore, NFP-E can deliver molecules to a target cell with minimal effect of the electric potential on the cell. Our experiments on HeLa cells confirm that NFP-E offers single cell selectivity, high transfection efficiency (>95%), qualitative dosage control, and very high viability (92%) of transfected cells.
将分子精确递送到单个细胞中对于生物技术研究人员来说非常感兴趣,因为这有助于推进治疗学、诊断学和药物输送方面的应用,朝着个性化医疗的承诺迈进。在过去十年中, bulk electroporation 技术在细胞转染中的应用显著增加,但该技术是非特异性的,需要高电压,导致效率变化和细胞活力降低。我们使用 nanofountain 探针 (NFP) 技术开发了一种新的电穿孔工具,它可以以比 bulk electroporation 或微注射更高效和温和的方式将分子递送到细胞中。在这里,我们通过用荧光标记的葡聚糖转染单个 HeLa 细胞来演示 NFP 电穿孔 (NFP-E),并对细胞进行成像以评估转染效率和细胞活力。我们对 NFP-E 机制的理论分析表明,施加电压会在 NFP 悬臂尖端和与尖端接触的细胞膜区域之间产生局部电场。因此,NFP-E 可以将分子递送到目标细胞,而对细胞的电势影响最小。我们在 HeLa 细胞上的实验证实,NFP-E 具有单细胞选择性、高转染效率 (>95%)、定性剂量控制和转染细胞的高活力 (92%)。